Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs.
about
Molecular mechanisms of etoposideThe E3 ubiquitin-ligase Bmi1/Ring1A controls the proteasomal degradation of Top2alpha cleavage complex - a potentially new drug targetMDM2 gene SNP309 T/G and p53 gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European CaucasiansGenetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population.MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group.Homozygous mdm2 SNP309 cancer cells with compromised transcriptional elongation at p53 target genes are sensitive to induction of p53-independent cell death.Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIα degradation in hepatocellular carcinoma cellsThe regulatory mechanism of the LY6K gene expression in human breast cancer cellsLentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer.Genetic variants in TP53 and MDM2 associated with male infertility in Chinese population.The risks, degree of malignancy and clinical progression of prostate cancer associated with the MDM2 T309G polymorphism: a meta-analysisNo evidence for association of the MDM2-309 T/G promoter polymorphism with prostate cancer outcomes.Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene.The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models.MDM2 SNP309 is associated with endometrial cancer risk.Interactions between MDM2 and TP53 Genetic Alterations, and Their Impact on Response to MDM2 Inhibitors and Other Chemotherapeutic Drugs in Cancer Cells.Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II.An NKX3.1 binding site polymorphism in the l-plastin promoter leads to differential gene expression in human prostate cancer.MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide.Mdm2 selectively suppresses DNA damage arising from inhibition of topoisomerase II independent of p53.Association between the P53 codon 72 polymorphism and nasopharyngeal cancer risk.A single-nucleotide polymorphism in the TP53 and MDM-2 gene modifies breast cancer risk in an ethnic Arab population.Among 45 variants in 11 genes, HDM2 promoter polymorphisms emerge as new candidate biomarker associated with radiation toxicity.
P2860
Q26776299-6370F251-E79B-44A5-877F-B4813329B8FEQ28472102-C2A0AD57-564D-4254-91C1-127D2CBAE872Q33330490-5F519B44-E048-49E7-B9FA-DCD89A978B55Q33557871-84A386C2-9B0E-4459-B872-C387EB447AAEQ34043467-5776A13A-DB33-4879-BFC9-04E7E686116EQ34496093-F53B00B5-1ACF-4F12-BFBE-A10A4DDFBD8EQ34681633-1F3E817E-2959-4A2D-919F-AFE06EF81AA6Q36385900-328195E4-1409-466D-8C42-4B9AEF0B73EDQ37003211-1DBC1A69-61E8-444E-B6AD-C978E420259AQ37074114-154A77C0-DAFD-4F97-88B4-EBC3E34CD1D7Q37074138-94E9667C-4218-4D1F-9190-AEAA229D79BDQ37195909-5E95269E-729A-40BF-96E7-155D716520C9Q37238851-890C8974-C31A-4A1E-A18E-7950CF8580A7Q37287418-ED8D742F-A95A-4658-AB69-84C6A0DBE21DQ37309516-B54D6F45-A326-495C-8B4E-232CA0A42B54Q37480094-7CD23867-BC98-471E-8841-C3953DAA509AQ38801085-4CE2933D-35DC-4346-A43F-2656EC1FA1BFQ38856207-2A7A6146-48B9-4428-A08A-712BFB361A96Q40320494-FCDF9480-6F39-4429-9695-B03C4D39982BQ50899909-6D6CC56D-E5DC-48D8-954F-B59C14DF4A77Q53127852-22CDC791-A312-450C-A700-39D53C5C43E4Q53288178-DEE79F63-11D2-4830-A131-4D367B546414Q54393867-21218476-04DD-45F1-A627-16456B687E91
P2860
Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Effect of a single nucleotide ...... oisomerase II-targeting drugs.
@en
type
label
Effect of a single nucleotide ...... oisomerase II-targeting drugs.
@en
prefLabel
Effect of a single nucleotide ...... oisomerase II-targeting drugs.
@en
P2093
P1433
P1476
Effect of a single nucleotide ...... oisomerase II-targeting drugs.
@en
P2093
Jin-Ming Yang
Mamatha S Nayak
William N Hait
P304
P356
10.1158/0008-5472.CAN-06-4533
P407
P577
2007-06-01T00:00:00Z